Medtronic CoreValve Meets Targets In Extreme-Risk Group; Panel Will Not Be Needed, FDA Says
This article was originally published in The Gray Sheet
The firm now expects to gain approval for the extreme-risk indication of its transcatheter aortic heart valve months earlier than earlier predicted following well-received pivotal trial data reported last week at the Transcatheter Cardiovascular Therapeutics meeting.
You may also be interested in...
Medtronic Touts New Products, Advantages Of TAVR In Post-CABG Patients
Medtronic launched new sizes of its repositionable transcatheter aortic valve replacement system. It also recently reported data for its first-generation CoreValve showing a benefit in high risk patients who had previously undergone coronary artery bypass surgery.
TAVR Performance Sustained In Long-Term Data
Five-year follow-up data on Edwards’ Sapien and two-year data on Medtronic’s CoreValve presented at the TCT conference in Washington, D.C., show sustained efficacy and safety for transcatheter aortic valves in patients too ill for surgery.
News Briefs: Medtronic’s CoreValve Approval; J&J Dx Unit Set For Sale; Google’s Glucometer Contact Lens
Medtronic gains FDA approval for its transcather CoreValve system months earlier than predicted. The Carlyle Group makes binding offer for J&J’s Ortho-Clinical Diagnostics business. Google is developing a wireless glucometer embedded within a contact lens. More news briefs.